Welcome to our dedicated page for Conformis news (Ticker: CFMS), a resource for investors and traders seeking the latest updates and insights on Conformis stock.
Conformis, Inc. (symbol: CFMS) is a leading medical technology company dedicated to enhancing orthopedic patient care. The company pioneers the development of patient-specific implants and instrumentation, offering unique advantages over traditional orthopedic solutions. Conformis' core mission is to optimize the fit and performance of implants by tailoring them to each patient's unique anatomy. This approach minimizes surgical trauma, preserves healthy tissue, and provides a more precise anatomic fit.
Conformis’ innovative product portfolio includes the Image-to-Implant® Platinum Services℠ Program and the Surgery-in-a-Box™ delivery system. These systems offer surgeons and patients fully personalized solutions and standardized options that combine the benefits of customization with the convenience of off-the-shelf systems. All implants come with single-use, patient-specific instruments, enhancing surgical efficiency and outcome.
Recently, Conformis has entered into a merger agreement with restor3d, Inc., a leader in 3D-printed orthopedic medical devices. This merger aims to create a dominant force in personalized 3D-printed medical devices by leveraging artificial intelligence-driven implant design, digital automation, and advanced osseointegrative biomaterials. The integration of Conformis' pioneering technology with restor3d’s expertise is anticipated to revolutionize the orthopedic industry further.
The merger has been unanimously approved by Conformis' Board of Directors and is expected to close by the end of Q3 2023, pending stockholder approval and customary closing conditions. Financial advisors for this transaction include UBS Investment Bank, with legal counsel from Hogan Lovells US LLP.
Conformis is headquartered in Billerica, Massachusetts, and continues to hold a strong position in the market, driven by its extensive portfolio of issued patents and pending patent applications covering personalized implants and patient-specific instrumentation for major joints.
Conformis Settles Patent Litigation with Stryker Corporation
On July 7, 2021, Conformis, Inc. (NASDAQ: CFMS) announced a settlement with Stryker Corporation that resolves patent litigation against Wright Medical Technology, Inc. and Tornier, Inc. The settlement includes a one-time payment from Stryker and a non-exclusive license for certain Conformis patents. CEO Mark Augusti emphasized the importance of their intellectual property in this resolution, highlighting the ongoing commitment to protecting their innovations.
Conformis, Inc. (NASDAQ: CFMS) will announce its Q2 2021 financial results on August 4, 2021, after market close. A conference call, led by CEO Mark Augusti and CFO Bob Howe, will take place at 4:30 p.m. Eastern Time on the same day. Investors can access the details via webcast or telephone, with a conference ID of 7040896. The company's innovative iFit Image-to-Implant technology offers customized joint replacements, aiming for better patient outcomes compared to conventional implants. More information will be available on their Investor Relations website.
Conformis has entered the Asia-Pacific market via an exclusive distribution agreement with XR Medical Group to sell its personalized knee replacement systems, including iTotal® CR & PS systems and iUni® implants. This partnership targets Hainan’s Boao Lecheng International Medical Tourism Pilot Zone, enhancing Conformis' global presence. The Asia-Pacific knee joint reconstruction market exceeds $1.7 billion and is poised for high growth due to rising knee disorders and medical tourism. The company aims to leverage XR Medical's track record for further expansion in the region.
Conformis, a leader in personalized orthopedic medical devices, announced that CEO Mark Augusti will present at the Oppenheimer MedTech Summit on May 26, 2021. A webcast of the virtual presentation will be available on the summit day. Additionally, Conformis management will host one-on-one meetings with attendees. For further inquiries or to schedule meetings, interested parties can contact Conformis Investor Relations. The presentation's replay will be accessible for 30 days on Conformis' website under the 'Events and Presentations' section.
Conformis, Inc. (NASDAQ: CFMS), a leader in personalized orthopedic medical devices, announced that CEO Mark Augusti and CFO Bob Howe will present at the Canaccord Genuity Musculoskeletal Conference on May 20, 2021, at 10:30 a.m. ET. A live webcast will be available, and one-on-one meetings with management can be arranged. Conformis specializes in developing customized knee and hip replacements using its proprietary iFit® technology, delivering individually sized implants to accommodate unique patient anatomies.
Conformis, Inc. (CFMS) announced FDA 510(k) clearance for its Identity Imprint Knee Replacement System on May 10, 2021. This system, available in cruciate retaining and posterior stabilized versions, offers a cost-effective solution with faster delivery times. Using a proprietary algorithm, it optimizes implant selection based on CT scans, enhancing surgical efficiency. The knee joint reconstruction market is projected to exceed $9 billion, with 1 million knee replacements expected in the U.S. this year, indicating a growing demand for efficient, personalized orthopedic solutions.
Conformis, Inc. (NASDAQ:CFMS) reported Q1 2021 results with total revenue of $13.8 million, down 16% year-over-year. Product revenue also decreased by 16%, with the Conformis Hip System revenue rising 49% to $0.7 million. The company achieved a gross margin of 45%, up 80 basis points year-over-year. Operating expenses remained flat at $15.3 million. A net loss of $11.5 million was reported, with cash equivalents totaling $104.6 million. The company anticipates revenue growth in Q2 and improved elective procedure volumes in the latter half of 2021.
Conformis, Inc. (NASDAQ:CFMS) announced FDA clearance for its patient-specific instrumentation (PSI) for Stryker’s Triathlon® Total Knee System. This marks the completion of the joint development agreement with Stryker, allowing Conformis to receive $11 million. CEO Mark Augusti emphasized the importance of this achievement despite recent global challenges and highlighted future plans for a long-term distribution agreement to manufacture and supply PSI to Stryker. This initiative aims to enhance shareholder value by meeting the growing demand for outpatient joint replacement surgeries.
Conformis, Inc. (NASDAQ: CFMS) announced a licensing agreement with Paragon 28, Inc. on April 19, 2021, allowing Paragon 28 to use Conformis' patient-specific instrument technology for its APEX 3D™ Total Ankle Replacement System. This partnership highlights the applicability and clinical appeal of Conformis' technology. Conformis specializes in customized joint replacement solutions, utilizing its proprietary iFit® Image-to-Implant® technology. The company remains committed to advancing personalized surgical instrumentation and implants.
Conformis, Inc. (NASDAQ: CFMS) will announce its first-quarter financial results for the period ended March 31, 2021, on May 5, 2021, post-market at 4:00 p.m. ET. The management team, including CEO Mark Augusti and CFO Bob Howe, will conduct a conference call and webcast at 4:30 p.m. ET to discuss results and provide updates. The company's patient-specific joint replacement implants demonstrated superior clinical outcomes in studies. For the earnings release, visit the Investor Relations website before the conference call.
FAQ
What is the market cap of Conformis (CFMS)?
What does Conformis, Inc. specialize in?
What is the recent merger announcement involving Conformis?
What are the benefits of Conformis' patient-specific implants?
What is the Image-to-Implant® Platinum Services℠ Program?
What is the Surgery-in-a-Box™ delivery system?
Who are the financial and legal advisors for the Conformis merger?
What are the expected benefits of the merger with restor3d?
Where is Conformis headquartered?
How can investors get more information about Conformis?